MediciNova Inc. (MNOV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.10+0.03 (+0.42%)
As of 3:11 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close7.07
Bid7.10 x 200
Ask7.11 x 200
Day's Range7.09 - 7.20
52wk Range2.74 - 10.16
1y Target EstN/A
Market Cap244.75M
P/E Ratio (ttm)-19.45
Avg Vol (3m)49,390
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research4 hours ago

    MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS

    MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 was previously tested in a randomized, double blind, placebo controlled Phase 2a clinical trial to evaluate its safety and effectiveness in relapsing MS patients.

  • Associated Pressyesterday

    MediciNova reports 3Q loss

    On a per-share basis, the La Jolla, California-based company said it had a loss of 8 cents. MediciNova shares have risen 100 percent since the beginning of the year. The stock has more than doubled in ...

  • GlobeNewswire16 days ago

    MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis

    LA JOLLA, Calif., Oct. 11, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the U.S. Food ...